Suppr超能文献

基于氟喹诺酮类药物的幽门螺杆菌根除方案。

Fluoroquinolone-based protocols for eradication of Helicobacter pylori.

作者信息

Rispo Antonio, Capone Pietro, Castiglione Fabiana, Pasquale Luigi, Rea Matilde, Caporaso Nicola

机构信息

Antonio Rispo, Pietro Capone, Fabiana Castiglione, Matilde Rea, Nicola Caporaso, Division of Gastroenterology, Department of Clinical Medicine and Surgery - University "Federico II" of Naples, 80131 Napoli, Italy.

出版信息

World J Gastroenterol. 2014 Jul 21;20(27):8947-56. doi: 10.3748/wjg.v20.i27.8947.

Abstract

Helicobacter pylori (H. pylori) is a widespread pathogen infecting about 40% of people living in urban areas and over 90% of people living in the developing regions of the world. H. pylori is well-documented as the main factor in the pathogenesis of peptic ulcer disease, chronic gastritis, and gastric malignancies such as cancer and mucosa-associated lymphoid tissue-lymphoma; hence, its eradication is strongly recommended. The Maastricht IV consensus, which focused on the management of H. pylori infection, set important new strategies in terms of treatment approaches, particularly with regards to first- and second-line treatment protocols and led to improved knowledge and understanding of H. pylori resistance to antibiotics. In recent years, various fluoroquinolone-based protocols, mainly including levofloxacin, have been proposed and effectively tested at all therapeutic lines for H. pylori eradication. The aim of the present paper is to review the scientific literature focused on the use of fluoroquinolones in eradicating H. pylori.

摘要

幽门螺杆菌(H. pylori)是一种广泛传播的病原体,感染了约40%的城市居民以及超过90%的世界发展中地区居民。幽门螺杆菌是消化性溃疡病、慢性胃炎以及胃癌和黏膜相关淋巴组织淋巴瘤等胃部恶性肿瘤发病机制中的主要因素,这一点已有充分记录;因此,强烈建议根除幽门螺杆菌。聚焦于幽门螺杆菌感染管理的马斯特里赫特IV共识在治疗方法方面制定了重要的新策略,特别是在一线和二线治疗方案方面,并增进了对幽门螺杆菌抗生素耐药性的认识和理解。近年来,已经提出了各种以氟喹诺酮类为基础的方案,主要包括左氧氟沙星,并在所有治疗线进行了有效测试以根除幽门螺杆菌。本文的目的是综述聚焦于使用氟喹诺酮类药物根除幽门螺杆菌的科学文献。

相似文献

1
Fluoroquinolone-based protocols for eradication of Helicobacter pylori.
World J Gastroenterol. 2014 Jul 21;20(27):8947-56. doi: 10.3748/wjg.v20.i27.8947.
2
Eradication of Helicobacter pylori infection: which regimen first?
World J Gastroenterol. 2014 Jan 21;20(3):665-72. doi: 10.3748/wjg.v20.i3.665.
4
Second-line rescue treatment of infection: Where are we now?
World J Gastroenterol. 2018 Oct 28;24(40):4548-4553. doi: 10.3748/wjg.v24.i40.4548.
5
Management of Helicobacter pylori infection after gastric surgery.
World J Gastroenterol. 2014 May 14;20(18):5274-82. doi: 10.3748/wjg.v20.i18.5274.
6
Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance.
Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017.
7
Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review.
World J Gastroenterol. 2015 Jan 7;21(1):139-54. doi: 10.3748/wjg.v21.i1.139.
8
Strategy for the treatment of Helicobacter pylori infection.
Curr Pharm Des. 2014;20(28):4489-500. doi: 10.2174/13816128113196660731.
9
High antibiotic resistance rate: A difficult issue for Helicobacter pylori eradication treatment.
World J Gastroenterol. 2015 Dec 28;21(48):13432-7. doi: 10.3748/wjg.v21.i48.13432.

引用本文的文献

1
Primary Resistance Pattern of to Antibiotics in Adult Population: A Systematic Review.
Infect Drug Resist. 2020 May 28;13:1567-1573. doi: 10.2147/IDR.S250200. eCollection 2020.
2
Antibiotic treatment for Helicobacter pylori: Is the end coming?
World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):183-98. doi: 10.4292/wjgpt.v6.i4.183.
3
Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.
World J Gastroenterol. 2015 Jun 7;21(21):6698-705. doi: 10.3748/wjg.v21.i21.6698.

本文引用的文献

1
Current recommendations for Helicobacter pylori therapies in a world of evolving resistance.
Gut Microbes. 2013 Nov-Dec;4(6):541-8. doi: 10.4161/gmic.25930. Epub 2013 Aug 5.
2
The antibiotic susceptibility patterns of uropathogenic Escherichia coli, with special reference to the fluoroquinolones.
J Clin Diagn Res. 2013 Jun;7(6):1027-30. doi: 10.7860/JCDR/2013/4917.3038. Epub 2013 Jun 1.
4
Seroprevalence of Helicobacter pylori infection and gastric mucosal atrophy in Bhutan, a country with a high prevalence of gastric cancer.
J Med Microbiol. 2013 Oct;62(Pt 10):1571-1578. doi: 10.1099/jmm.0.060905-0. Epub 2013 Jul 5.
5
Precancerous lesions in the stomach: from biology to clinical patient management.
Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):205-23. doi: 10.1016/j.bpg.2012.12.007.
6
Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre.
Ir J Med Sci. 2013 Dec;182(4):693-5. doi: 10.1007/s11845-013-0957-3. Epub 2013 Apr 27.
7
Efficacy of two levofloxacin-containing second-line therapies for Helicobacter pylori: a pilot study.
Helicobacter. 2013 Oct;18(5):378-83. doi: 10.1111/hel.12056. Epub 2013 Apr 21.
9
The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria.
Lancet Infect Dis. 2013 Feb;13(2):155-65. doi: 10.1016/S1473-3099(12)70317-1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验